TGTX's Quality Score rose 2 points on Fri, Oct 30, to 21. Traded heavy volume (2 chart checks started).
Follow TGTX's trial news. Pro members can get an alert when TG Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 13% so far from Oct 22 to Nov 2.
| Outperforming | Up 103% this year vs the S&P's +11% |
| Latest filing | 10-Q, Aug 5 |
ReportReports Mon Nov 9, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +1.5% on average. Past reports ›
After its last 4 reports it closed +1.5% on average, higher 2 of 4 times.
Director Laurence N Charney sold 5,000 shares on Sep 10.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Exceptionalfor quality, not price, 10 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. TGTX scores 21 today, against a median of 12 over its last 20 recorded sessions.
TGTX is #1 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Free cash flow over four quarters: TGTX $17.4M, PTCT -$39.8M, MIRM -$229M, VERA -$339M.
Reports Mon Nov 9, before the open (in 7 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase in selling, general and administrative costs during the three and six months ended June 30, 2026 was primarily due to an increase in marketing and media spend, and personnel costs associated with the commercialization of BRIUMVI.”
TGTX's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total global revenue | about $950M |
“The period over period increase in R&D was also attributable to higher clinical trial-related expenses associated with our development pipeline during the period.”
From its results filing (SEC filing · Aug 3)
Its share count grew 6% a year over 3 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 3, 2026 | -1.9% | -11.3% | -4.4% |
| May 6, 2026 | +0.4% | +16.3% | +17.8% |
| Feb 26, 2026 | -4.3% | +4.2% | -1.6% |
Sales grew in three of the last four years, to $616M in 2025. It made a profit in three of the five years.
One insider sold $275K across 1 filing in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: TGTX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
“Competition in the pharmaceutical and biotechnology industries is intense.”
TGTX scores 21 today, which Breakaway calls Exceptional. It is #1 of 291 in Biotech by Quality Score, with 10 of 14 chart checks firing. Up 13% so far from Oct 22 to Nov 2. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
TGTX scores 21 today, which Breakaway calls Exceptional (20 or more). That is #1 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TGTX's 21.
One insider sold $275K across 1 filing in the last 6 months. No open-market buys on record. The newest is Laurence N. Charney, Director, who sold $275K on Sep 10.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.